Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study With an Open-Label Extension to Evaluate Safety, Pharmacodynamics (PD) and Efficacy of GV101 in Friedreich's Ataxia

NCT07870590 is registered in ClinicalTrials.gov with Graviton Bioscience Corporation as lead sponsor.

NCT NCT07870590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study With an Open-Label Extension to Evaluate Safety, Pharmacodynamics (PD) and Efficacy of GV101 in Friedreich's Ataxia
Lead sponsor
Graviton Bioscience Corporation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
October 31, 2027
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

friedreich's ataxia